Sim Mei Yi (Mei Yi Sim)

ORCID

Publication Activity (10 Years)

Years Active: 2017-2021
Publications (10 Years): 4

Top Venues

Nature communications

Scientific reports

PloS one

This page only lists publications with an associated author ORCID identifier.

Publications

Min Thura, Abdul Qader Al-Aidaroos, Abhishek Gupta, Cheng Ean Chee, Soo Chin Lee, Kam Man Hui, Jie Li, Yeoh Khay Guan, Wei Peng Yong, Jimmy So, Wee Joo Chng, Chin Hin Ng, Jianbiao Zhou, Ling Zhi Wang, John Shyi Peng Yuen, Henry Sun Sien Ho, Sim Mei Yi, Edmund Chiong, Su Pin Choo, Joanne Ngeow, Matthew Chau Hsien Ng, Clarinda Chua, Eugene Shen Ann Yeo, Iain Bee Huat Tan, Joel Xuan En Sng, Nicholas Yan Zhi Tan, Jean Paul Thiery, Boon Cher Goh, Qi Zeng
Author Correction: PRL3-zumab as an immunotherapy to inhibit tumors expressing PRL3 oncoprotein. Nature communications 12 (1) (2021)
Min Thura, Abdul Qader Al-Aidaroos, Abhishek Gupta, Cheng Ean Chee, Soo Chin Lee, Kam Man Hui, Jie Li, Yeoh Khay Guan, Wei Peng Yong, Jimmy So, Wee Joo Chng, Chin Hin Ng, Jianbiao Zhou, Ling Zhi Wang, John Shyi Peng Yuen, Henry Sun Sien Ho, Sim Mei Yi, Edmund Chiong, Su Pin Choo, Joanne Ngeow, Matthew Chau Hsien Ng, Clarinda Chua, Eugene Shen Ann Yeo, Iain Bee Huat Tan, Joel Xuan En Sng, Nicholas Yan Zhi Tan, Jean Paul Thiery, Boon Cher Goh, Qi Zeng
PRL3-zumab as an immunotherapy to inhibit tumors expressing PRL3 oncoprotein. Nature communications 10 (1) (2019)
Sim Mei Yi, John Shyi Peng Yuen, Mei Lin Go
Anti-survivin effect of the small molecule inhibitor YM155 in RCC cells is mediated by time-dependent inhibition of the NF-κB pathway. Scientific reports 8 (1) (2018)
Sim Mei Yi, Hung Huynh, Mei Lin Go, John Shyi Peng Yuen
Action of YM155 on clear cell renal cell carcinoma does not depend on survivin expression levels. PloS one 12 (6) (2017)

Sim Mei Yi.css-eqlu8i{font-size:small;padding-left:4px;} (Mei Yi Sim)

Publication Activity (10 Years)

Top Topics

Top Venues

Sim Mei Yi (Mei Yi Sim)